Results 121 to 130 of about 27,163 (253)
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets
MedComm, Volume 7, Issue 2, February 2026.This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen +5 more
wiley +1 more source
Unilateral optic neuritis and thinning of retinal layers in the affected and unaffected eyes
Acta Ophthalmologica, Volume 104, Issue 1, Page e84-e94, February 2026.Abstract Purpose Multiple sclerosis (MS)‐related optic neuritis (ON) causes thinning of inner retinal layers. It remains unclear whether unilateral MSON also affects the unaffected contralateral eye. The purpose of this study was to compare macular retinal layer thicknesses in MS eyes with unilateral optic neuritis (MSON), their unaffected ...
Sanna Leinonen +4 more
wiley +1 more source
Natalizumab therapy, 2013 [PDF]
, 2014 Multiple sclerosis (MS) is the most common chronic disease of the central nervous system in young adults. No curative therapy is known. Currently, six drugs are available that can reduce the activity of MS.
Bencsik, Krisztina +2 more
core
European Journal of Neurology, Volume 33, Issue 2, February 2026.This graphical abstract shows that serum NfL was evaluated alongside clinicodemographic variables that were reduced using principal component analysis (PCA). These components were then incorporated into a combined prognostic model. The addition of serum NfL did not result in any significant improvement in prognostic accuracy in the pooled cohort ...
Nahid Moradi +18 more
wiley +1 more source
Therapeutic Advances in Neurological DisordersAn expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently.
Darin T. Okuda +7 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2016 Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj +1 more source
Cryptococcal Meningitis Reported With Fingolimod Treatment [PDF]
, 2022 Maurizio Del Poeta +11 more
openalex +1 more source
A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis
European Journal of Neurology, Volume 33, Issue 2, February 2026.This was a national multicenter comparative effectiveness research study using data from the Danish Multiple Sclerosis Registry. Relapsing–remitting multiple sclerosis patients initiating ocrelizumab or natalizumab between January 2018 to April 2023 were included.
Camilla Maersk‐Moller +18 more
wiley +1 more source
Acta Neurologica TaiwanicaObjective: The purpose of this study was to investigate the effects of Crocin on brain neuroterophins, cognition, sensory and motor dysfunction and compare to fingolimod effects in toxic-induced demyelination with Ethidium Bromide (EB) in female Wistar ...
Rouholah Fatemi +3 more
doaj +1 more source